Dr. Pejman E. Cohan, MD

Dr. Cohan practices at Beverly Hills Endosurgical Center in Beverly Hills, California.

Dr. Cohan's NPI, 1225064884, was assigned on June 24, 2006. Dr. Cohan graduated from David Geffen School of Medicine at UCLA in 1995. Dr. Cohan holds California license A61196.

Dr. Cohan's primary practice is Beverly Hills Endosurgical Center, at 150 North Robertson Blvd, Suite 110, Beverly Hills, CA 90211. The practice phone is (323) 202-2023.

Dr. Cohan's primary practice is Beverly Hills Endosurgical Center in Beverly Hills, California. Dr. Cohan is also affiliated with Ronald Reagan UCLA Medical Center. Dmand AI also links Dr. Cohan to 2 more hospitals, 1 physician office and 1 home health agency, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Cohan practices, 6 sites in all. Vendor and product names are available with a free account.

Endocrinology, diabetes and metabolism is Dr. Cohan's primary specialty in the NPI Registry, under taxonomy code 207RE0101X. Dr. Cohan is board certified in endocrinology, diabetes and metabolism by the American Board of Internal Medicine. Dr. Cohan is licensed in California.

Dmand AI lists chronic diabetes, diabetic emergency, enlarged thyroid, high cholesterol, osteoporosis, overactive thyroid, parathyroid gland disorder and testicular dysfunction among the conditions Dr. Cohan treats.

CMS data shows 5,024 Medicare services from Dr. Cohan across 40 procedure codes in 2024, for 207 Medicare patients. Medicare paid $149,340 for them. Every service was in an office.

CMS counts 207 Medicare patients who saw Dr. Cohan in 2024. The largest group is 65 to 74, with 98 patients. 75% of them have high cholesterol, and 71% have diabetes. Their average risk score is 1.26, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Cohan's median patient age at 64, with 77% women.

In 2024, Dr. Cohan wrote 2,824 Medicare Part D claims for 206 patients. 43% of them were for generic drugs. CMS names the drug for 2,187 of them, across 64 drugs with 11 or more claims each, at $1,229,556 in total drug cost. In 2023, CMS named 2,724 claims across 79 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Cohan for performance year 2024, reported individually. Dr. Cohan accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 30 papers to Dr. Cohan, published from 2004 to 2021. 2012 was the busiest year, with 4. The most frequent topics are Pituitary Neoplasms, Adenoma and Hypopituitarism. Dr. Cohan has published most often in J Neurosurg. Dr. Cohan's most frequent co-authors are Daniel F. Kelly, MD, Ronald S. Swerdloff, MD and Garni Barkhoudarian, MD.

Dmand AI links Dr. Cohan to 1 clinical trial. Conditions studied include Gigantism and Acromegaly.

CMS Open Payments shows 1,079 general payments to Dr. Cohan from 73 drug and device companies from 2016 to 2025. Honoraria make up the largest share, 40% of the total. Corcept Therapeutics paid the most, $53,589.

Dmand AI lists 4 awards for Dr. Cohan, most recently Top Doctor in 2020.

Dr. Cohan graduated from David Geffen School of Medicine at UCLA in 1995. Dr. Cohan is a member of AACE.

Dr. Cohan is in network with 1 carrier, including CMS Medicare. Medicare plans come from the most carriers, 1. Check the plan with the practice before a visit.